Sandip Kapadia Sells 1,775 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction on Monday, January 27th. The stock was sold at an average price of $38.05, for a total value of $67,538.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00.

Harmony Biosciences Trading Up 1.0 %

Shares of HRMY opened at $38.82 on Thursday. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The company has a market capitalization of $2.21 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. The stock has a fifty day moving average of $35.20 and a two-hundred day moving average of $35.22. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. During the same period in the prior year, the firm posted $0.63 earnings per share. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. As a group, analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Raymond James reissued an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research report on Monday. Oppenheimer restated an “outperform” rating and set a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Mizuho increased their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Finally, Cantor Fitzgerald boosted their price target on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Harmony Biosciences presently has an average rating of “Buy” and an average price target of $55.00.

Institutional Trading of Harmony Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares during the last quarter. Mendota Financial Group LLC raised its stake in Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after purchasing an additional 965 shares during the period. CWM LLC raised its stake in Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after purchasing an additional 775 shares during the period. KBC Group NV grew its stake in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after buying an additional 819 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Harmony Biosciences during the 3rd quarter valued at $74,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.